Modulation of microglial activation by antidepressants
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Recent studies have suggested that microglial activation plays a key role in the pathogenesis of depression. In fact, neuroinflammation is associated with a phenotypic change of microglia, consisting of morphological differences, increased release of cytokines and oxidative stress products, which may contribute to the development and maintenance of depression. Antidepressants, including selective serotonin re-uptake inhibitors and serotonin–norepinephrine reuptake inhibitors, have been shown to act on the immune and oxidative stress mechanisms commonly found to be disrupted in depression. Thus, the inhibition of microglial activation may be one of the mechanisms through which they exert an antidepressant action. Aim: This is the first review summarising in vitro and ex vivo studies investigating the effects of different classes of antidepressants on microglia activation, by examining cellular changes and/or via measuring the production of immune and/or oxidative stress signalling molecules, in microglia models of neuroinflammation with either lipopolysaccharide (LPS) or cytokines. A total of 23 studies were identified, 18 using LPS stimulation and 5 using cytokines stimulation. Results: Overall, the studies show that antidepressants, such as selective serotonin re-uptake inhibitors, serotonin–norepinephrine reuptake inhibitors, monoamine oxidase inhibitors and tricyclic antidepressants prevented microglial activation, including reduced microglial reactivity and decreased immune and oxidative stress products, in both models. However, specific antidepressants, such as bupropion and agomelatine did not prevent interferon-gamma (IFN-γ)-induced microglial activation; and for other antidepressants, including phenelzine, venlafaxine and sertraline, the results of different studies were inconsistent. Conclusions: Overall, results summarised in this review support the hypothesis that the action of at least certain classes of antidepressants may involve regulation of microglial activation, especially when in presence of increased levels of inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Santos, A. G., da Rocha, G. O., & de Andrade, J. B. (2019) · Scientific Reports · doi:10.1038/s41598-018-37186-2 · Cited by 8,495
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 1×
“In fact, according to findings from genetic data analyses (Martinez and Gordon, 2014; Ransohoff, 2016), this classification method needs reconsideration of the restrictive M1/M2 activation paradigm to fully describe the broad diversity of microglial response.”
BackgroundHOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Hammond, T. R., Dufort, C., Dissing-Olesen, L., Giera, S., Young, A., Wysoker, A., Walker, A. J., Segel, M., Nemesh, J., Saunders, A., et al. (2018) · doi:10.1101/406140 · Cited by 2,225 · cited 2×
“…numerous functions of microglia, integrating both immune and metabolic cell characteristics, would be achieved by obtaining multiple phenotypes, each of which is associated with a different molecular signature (Bennett et al., 2016; Crain et al., 2013; Hammond et al., 2019; Hickman et al., 2013).”
BackgroundHippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932 · cited 1×
“The hippocampus is an area of the brain responsible for neurogenesis, the process through which new neurons are generated in the brain, and it is known to regulate both memory and emotion, all of which are dysregulated patients with depression (Boldrini et al., 2014, 2012; Sheline et al., 1996).”
BackgroundNew tools for studying microglia in the mouse and human CNS
Bennett, M. L., Bennett, F. C., Liddelow, S. A., Ajami, B., Zamanian, J. L., Fernhoff, N. B., Mulinyawe, S. B., Bohlen, C. J., Adil, A., Tucker, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525528113 · Cited by 1,804
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710 · cited 1×
“Since microglia can disrupt neurogenesis via the production of inflammatory cytokines (Hickman et al., 2018), antidepressants treatment may exert its properties via inhibiting microglia-induced cytokines production and ultimately enhance brain plasticity and decrease depressive symptoms.”
BackgroundA polarizing question: do M1 and M2 microglia exist?
Ransohoff, R. M. (2016) · Nature Neuroscience · doi:10.1038/nn.4338 · Cited by 1,573
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966 · cited 2×
“It is also well-established that inflammation within the central nervous system (CNS) significantly contributes to the development of psychiatric diseases (Stephenson et al., 2018), whereby pro-inflammatory cytokines, such as interleukin 1 beta (IL-1β), IL-6 and tumour necrosis factoralpha (TNF-α) are significantly ra…”
BackgroundThe GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress
Koo, J. W., & Duman, R. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708092105 · Cited by 862 · cited 2×
“…stress products (Harry and Kraft, 2008; Lehnardt, 2010), which can ultimately disrupt neuronal differentiation and increase cell death, similar to what is often observed in pre-clinical (Goshen et al., 2008; Koo and Duman, 2008) and post-mortem studies in depression (Boldrini et al., 2013).”
ResultSteiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., & Yirmiya, R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002055 · Cited by 762 · cited 2×
“In fact, it is clear that dysfunctions in excitatory and/or inhibitory glutamate and gamma-aminobutyric acid (GABA) signalling mechanisms may play a critical role in depression (Fee et al., 2017; Goshen et al., 2008; Luscher and Fuchs, 2015; Luscher et al., 2011).”
BackgroundResultThe role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Steiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568 · cited 1×
“…Wang et al., 2018b) and clinical studies in depression, including neuroimaging (Holmes et al., 2018) and post-mortem studies (Schnieder et al., 2014; Steiner et al., 2008, 2011), have shown an increase in the numbers of activated microglia, in particular, in individuals with suicidal ideation.”
BackgroundWang, Y.-L., Han, Q.-Q., Gong, W.-Q., Pan, D.-H., Wang, L.-Z., Hu, W., Yang, M., Li, B., Yu, J., & Liu, Q. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1054-3 · Cited by 438
Boldrini, M., Santiago, A. N., Hen, R., Dwork, A. J., Rosoklija, G. B., Tamir, H., Arango, V., & John Mann, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.5 · Cited by 361
Boldrini, M., Hen, R., Underwood, M. D., Rosoklija, G. B., Dwork, A. J., Mann, J. J., & Arango, V. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.024 · Cited by 348 · cited 1×
“The hippocampus is an area of the brain responsible for neurogenesis, the process through which new neurons are generated in the brain, and it is known to regulate both memory and emotion, all of which are dysregulated patients with depression (Boldrini et al., 2014, 2012; Sheline et al., 1996).”
BackgroundHolmes, S. E., Hinz, R., Conen, S., Gregory, C. J., Matthews, J. C., Anton-Rodriguez, J. M., Gerhard, A., & Talbot, P. S. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.005 · Cited by 346
Kubera, M., Lin, A.-H., Kenis, G., Bosmans, E., van Bockstaele, D., & Maes, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00012 · Cited by 343
Fee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Interferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297 · cited 2×
“To support this evidence, different studies have shown that a high proportion of cancer and hepatitis C patients who receive cytokine including interferon-alpha (IFN-α) therapy develops symptoms of depression that are indistinguishable from those found in MDDs (Denicoff et al., 1987; Schäfer et al., 2007; Su et al., 2…”
BackgroundResultEnvironmental exposures and depression: biological mechanisms and epidemiological evidence
van den Bosch, M., & Meyer-Lindenberg, A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-044106 · Cited by 254
Sanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239 · cited 2×
“…signals on one hand (Harry and Kraft, 2008; Lehnardt, 2010), and the ability of antidepressants to govern microglial cell function on the other (Sanacora and Banasr, 2013), there is now a growing belief that one way for antidepressants to work is to inhibit microglial activation and ultimately…”
BackgroundHepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.037 · Cited by 225 · cited 1×
“In fact, IFN-α treatment can lead to the development of depression in up to 30% of patients within the first 3 months of therapy (Schaefer et al., 2012).”
BackgroundSelf-citationZou, W., Feng, R., & Yang, Y. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197267 · Cited by 224 · cited 2×
“, 2018), whereby pro-inflammatory cytokines, such as interleukin 1 beta (IL-1β), IL-6 and tumour necrosis factoralpha (TNF-α) are significantly raised in serum and cerebral spinal fluid (CSF) of, at least, a subgroup of patients suffering from depression (Wang and Miller, 2018; Zou et al., 2018).”
BackgroundAnti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells
Liu, D., Wang, Z., Liu, S., Wang, F., Zhao, S., & Hao, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.033 · Cited by 221 · cited 22×
“…of inflammation in primary rat and mice microglia cultures (Dhami et al., 2013; Du et al., 2014, 2016; Liu et al., 2011; Zhang et al., 2012) and mice BV2 microglia cultures (Liu et al., 2011; Park et al., 2019; Tynan et al., 2012; Yang et al., 2014), and in mice hippocampi (Rodrigues et al., 2018).”
BackgroundResultInfluentialAntidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212 · cited 4×
“in 2016 has discussed the antiinflammatory effect of antidepressants on microglia/macrophage M1 polarisation, they have only reported studies on cells exposed to selected classes of antidepressants (SSRIs, monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs)) where only inflammation, but not oxida…”
BackgroundInfluentialMicroglia of Prefrontal White Matter in Suicide
Schnieder, T. P., Trencevska, I., Rosoklija, G., Stankov, A., Mann, J. J., Smiley, J., & Dwork, A. J. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000107 · Cited by 202 · cited 2×
“…(Lehmann et al., 2016; Wang et al., 2018b) and clinical studies in depression, including neuroimaging (Holmes et al., 2018) and post-mortem studies (Schnieder et al., 2014; Steiner et al., 2008, 2011), have shown an increase in the numbers of activated microglia, in particular, in individuals with…”
BackgroundAntidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide
Hashioka, S., Klegeris, A., Monji, A., Kato, T., Sawada, M., McGeer, P. L., & Kanba, S. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.022 · Cited by 198 · cited 16×
“In contrast, post-mortem studies, have investigated microglial reactivity through other markers, including major histocompatibility complex class II (MHC-II), CD40, CD68 and the peripheral-type benzodiazepine receptor.”
BackgroundResultInfluentialGABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149 · cited 1×
“In fact, it is clear that dysfunctions in excitatory and/or inhibitory glutamate and gamma-aminobutyric acid (GABA) signalling mechanisms may play a critical role in depression (Fee et al., 2017; Goshen et al., 2008; Luscher and Fuchs, 2015; Luscher et al., 2011).”
BackgroundRescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants
Borsini, A., Alboni, S., Horowitz, M. A., Tojo, L. M., Cannazza, G., Su, K.-P., Pariante, C. M., & Zunszain, P. A. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.05.006 · Cited by 126
Self-citationFluoxetine protects neurons against microglial activation-mediated neurotoxicity
Zhang, F., Zhou, H., Wilson, B. C., Shi, J.-S., Hong, J.-S., & Gao, H.-M. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70066-9 · Cited by 123 · cited 24×
“…is mediated by inhibition of nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB), mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases (ERK1/2) pathways (Du et al., 2014; Liu et al., 2011; Park et al., 2019; Yang et al., 2014; Zhang et al., 2012).”
BackgroundResultInfluentialBoldrini, M., Galfalvy, H., Dwork, A. J., Rosoklija, G. B., Trencevska-Ivanovska, I., Pavlovski, G., Hen, R., Arango, V., & Mann, J. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.022 · Cited by 116 · cited 1×
“Once produced, cytokines, and particularly pro-inflammatory cytokines, can alter neurogenesis, a process potentially disrupted in depression, and required for antidepressant efficacy (Boldrini et al., 2013, 2019).”
BackgroundObuchowicz, E., Kowalski, J., Labuzek, K., Krysiak, R., Pendzich, J., & Herman, Z. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500547x · Cited by 115
Borsini, A., Cattaneo, A., Malpighi, C., Thuret, S., Harrison, N. A., MRC ImmunoPsychiatry Consortium, Zunszain, P. A., & Pariante, C. M. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx083 · Cited by 113 · cited 1×
“Indeed, evidence coming from our lab has shown that in vitro treatment of human hippocampal neuronal progenitors with exogenous IL-1β, IL-6 or IFN-α can dramatically reduce cell proliferation and neurogenesis, and increase apoptosis (Borsini et al., 2017, 2018, 2020).”
BackgroundSelf-citationAnti-depressant medication use and C-reactive protein: Results from two population-based studies
Hamer, M., Batty, G., Marmot, M. G., Singh-Manoux, A., & Kivimäki, M. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.09.013 · Cited by 71 · cited 2×
“, 2007) and clinical models of neuropsychiatric conditions (Hamer et al., 2011; Hashioka et al., 2009).”
Background
Cited by
Selected biomarkers of depression: what are the effects of cytokines and inflammation
Harsanyi, S., Kupcova, I., Danisovic, L., & Klein, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010578 · Cited by 299
TGF-β Signaling in Microglia: A Key Regulator of Development, Homeostasis and Reactivity
Li, L., Sun, B., Harris, O. A., & Luo, J. (2024) · Biomedicines · doi:10.3390/biomedicines12112468 · Cited by 38
“Antidepressants may be potential candidates for reducing microglial reactivity in neurodegenerative diseases [93].”
Ramos‐Cejudo, J., Corrigan, J. K., Zheng, C., Swinnerton, K. N., Jacobson, S. R., La, J., Betensky, R. A., Osorio, R. S., Madanes, S., Pomara, N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13853 · Cited by 11
Resolving a paradox: antidepressants, neuroinflammation, and neurodegeneration
Rajkumar, R. P. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00068 · Cited by 9
Metadata
- Authors
- Mariani, N., Everson, J., Pariante, C. M., & Borsini, A.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2022-01-29
- Volume
- 36
- Issue
- 2
- Pages
- 131-150
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W4210263763
- Cited by
- 89
- References
- 38
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.